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Abstract 
Proton therapy is very sensitive to uncertainties introduced during treatment planning and dose 
delivery. PET imaging of proton induced positron emitter distributions is the only practical ap-
proach for in vivo, in situ verification of proton therapy. This article reviews the current status of 
proton therapy verification with PET imaging. The different data detecting systems (in-beam, 
in-room and off-line PET), calculation methods for the prediction of proton induced PET activity 
distributions, and approaches for data evaluation are discussed. 
Key words: proton therapy, proton range verification, PET imaging. 
Introduction 
Proton therapy is one of the most precise mo-
dalities of external radiation therapy. Unlike a photon 
beam which has a high entrance dose and decreases 
gradually while passing through the body, a proton 
beam can penetrate through tissues and deposit most 
of its energy near the end of its track, known as the 
Bragg peak (Figure 1). In clinics, a spread-out Bragg 
peak (SOBP) field can be generated by using protons 
of multiple energies. Compared to the conventional 
photon therapy, proton therapy has a much lower 
entrance dose and no dose beyond the target volume. 
Because of this unique depth-dose characteristic, 
proton therapy is able to deliver highly conformal 
radiation fields to target volumes. Therefore, it is 
preferred for tumors with irregular shapes and/or 
around critical structure. Also, because of its much 
lower integral dose (approximately 60% lower than in 
photon therapy [1]), proton therapy is preferred for 
the treatments of pediatric patients, when the proba-
bility of secondary tumor caused by radiation dose to 
the normal tissue is a concern. For these reasons, the 
number of proton therapy centers is growing rapidly 
worldwide despite the high capital  cost. Several 
companies are currently developing compact proton 
treatment equipment, which is expected to greatly 
reduce the cost of proton therapy.  
However, proton therapy is also more sensitive 
to uncertainties in treatment planning and delivery 
compared to photon therapy. Proton range inaccuracy 
is particularly of concern [2, 3]. Due to the steep gra-
dient of dose fall-off at the Bragg peak region, uncer-
tainties in proton therapy planning have more severe 
consequences than in photon therapy. A range error 
could mean a portion of a tumor not receiving any 
radiation dose at all (under-shooting), or the normal 
tissue lying distal to the beam receiving a full dose 
(over-shooting). Range uncertainties could potentially 
prevent the full utilization of the physics advantage of 
proton therapy. For example, in the case of a tumor in 
close proximity to a critical structure, shown in Figure 
2, the optimal arrangement of one single beam stop-
ping in the tumor right in front of the critical structure 
(a) would have to be substituted with a more con-
servative arrangement of two patched beams (b) to 
protect the critical structure from possible radiation 
damage.  
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Fig 1. The comparison of dose-depth profiles for photon and proton 
therapies. 
 
Uncertainties in proton therapy arise from sev-
eral sources. In the treatment planning process, range 
uncertainties can be caused by stochastic errors (CT 
noise), CT artifacts, CT resolution (partial volume 
effects), and most importantly, the Hounsfield unit 
(HU) conversion method [2, 3]. Currently most com-
mercial planning systems are based on analytical 
pencil-beam dose calculation algorithms, which pro-
ject the range based on the water-equivalent depth in 
the patient using empirical HU conversion schemes to 
translate CT scans into relative stopping powers. Such 
conversion formalism cannot be directly validated in 
vivo, causing intrinsic range uncertainties in treat-
ment planning calculations. In addition, since CT 
scans provide only electron density distribution, the 
analytical algorithm cannot correctly model some 
other physics effects, such as multiple Coulomb scat-
tering and non-elastic nuclear reactions, especially at 
interfaces of alternating low-  and high-  density tis-
sues. Therefore, further range degradation is expected 
in case of complex geometries and density variations. 
During treatment, further uncertainties are intro-
duced due to setup and positioning errors, organ mo-
tions, and change of anatomical structures, such as the 
shrinkage of tumors or change of weights.  
  
 
Fig 2. (a) The optimal beam arrangement of one proton beam stopped in 
a target volume right in front of a critical structure. (b) The conservative 
beam arrangement of two patched beams to avoid possible damage to the 
critical structure.  
 
Verification of proton therapy is very important 
to ensure treatment planning and delivery systems 
are functioning properly. Furthermore, understand-
ing the uncertainties in proton therapy is important 
for the determination of the safety margins in treat-
ment planning. Since proton beams stop completely 
in the body, direct in vivo treatment monitoring is 
difficult. Point dose measurement with implanted 
dosimeter has been proposed for range monitoring, 
but the approach is invasive and involves splitting an 
SOBP field into two opposite ‘sloped’ subfields [4]. 
Three methods are being investigated for in vivo, 
non-invasive imaging of dosimetry for proton thera-
py. MRI has been used to measure the physiological 
changes in proton irradiated tissues, such as the fatty 
replacement of vertebra bone marrow, however this 
cannot be done in-situ because the physiological 
changes take several weeks to develop [5]. The 
prompt gamma imaging approach uses prompt 
gamma emission produced by inelastic interactions of 
incident protons and target nuclei to verify the proton 
dose delivery and range [6-8]. The prompt gamma 
rays have a high production rate and can be detected 
within a few nanoseconds after the nuclear reactions. 
However, most of the emissions correlated to proton 
range are in the energy range of 4~10 MeV, and there 
are no practical detectors available for prompt gamma 
detection. Currently the only practical approach is the 
PET imaging of proton induced position emitters 
[9-15]. In this review the current status of investiga-
tions on PET verification of proton therapy and the 
quantitative methods used are discussed. 
Rationale for Proton therapy verification with 
PET 
Using PET imaging for the verification of hadron 
therapy was first proposed by Maccabee et al in 
1969[16]. During an ion beam irradiation, positron 
emitters are produced on the beam path through nu-
clear fragmentation reactions, leaving a footprint of 
radiotracers that can be imaged with a PET scanner. 
While for heavier ions (such as 12C or 16O beams) the 
fragmentation reaction can happen on both the inci-
dent particles (projectile fragmentation) and target 
nuclei (target fragmentation), for a proton beam only 
target fragmentation is possible. Major reaction 
channels are listed in Table 1[17, 18]. Parodi et al cal-
culated the integral yield of several species of radio-
nuclide (15O, 11C, 30P, 38K, etc) for a clinically planned 
treatment field with Monte Carlo simulations [19]. In 
soft tissues the most important radionuclide species 
are 11C, 13N and 15O. Due to the high oxygen density in 
tissues and the relatively short half-life (therefore high 
decay constant) of 15O, usually 15O is the dominant 
contribution to the PET measurement during (for  Theranostics 2013, Vol. 3, Issue 10 
 
http://www.thno.org 
733 
synchrotron-based proton facility only) or immedi-
ately after irradiation. However, because of the short 
half live of 15O,  11C becomes the dominant nuclide 
after a few minutes. Figure 3 shows the relative con-
tributions of the three nuclide species at different time 
points when only radioactive decay presents. Because 
the PET signal originates from contributions of mixed 
radionuclide species with different decay rates, PET 
verification of proton therapy is very sensitive to the 
time course of data acquisition.  
Table 1. Major nuclear reaction channels for proton induced 
positron emitter productions. 
Radionuclide  Half live (min)  Nuclear reaction channels / 
Threshold energies (MeV) 
15O  2.037  16O(p,pn)15O/16.79 
11C  20.385  12C(p,pn)11C/20.61,  
14N(p,2p2n)11C/3.22,  
16O(p,3p3n)11C/59.64 
13N  9.965  16O(p,2p2n)13N/5.66,  
14N(p,pn)13N/11.44 
30P  2.498  31P(p,pn)30P/19.7 
38K  7.636  40Ca(p,2p2n)38K/21.2 
 
 
Dose deposition and positron emitter production 
in proton therapy are two different processes in har-
don therapy. A heavy charged particle loses energy 
primarily through the ionization and excitation of 
atoms. When passing through the tissue, the moving 
charged particle deposits dose by imparting energy to 
atomic electrons through electromagnetic forces. Pos-
itron emitter production, on the other hand, involves 
nuclear reactions, and the yield depends on several 
factors including the proton fluence, the cross sections 
of specific reaction channels (which are ener-
gy-dependent) and the density of target nuclei. While 
for a mono-energetic ion beam (for example, a 12C 
beam) an activity peak close to the Bragg peak can be 
found due to projectile fragmentation reactions, for 
proton therapy (in which only target fragmentation 
reactions are possible) the PET activity distribution is 
completely different from the dose distribution, with 
almost no activities produced within ~1 cm before the 
Bragg peak due to the energy thresholds of nuclear 
reactions [20]. Therefore PET activity and dose dis-
tributions cannot be compared directly. For treatment 
verification the PET measurements have to be com-
pared with predicted activity distributions or other 
reference images. 
PET data acquisition 
There are three operational modalities for PET 
verification of proton therapy, based on the PET sys-
tem used for data acquisition, as illustrated in Figure 
4. In-beam PET uses build-in PET detectors attached 
to the proton treatment system so that PET data can 
be acquired during (for synchrotron-based proton 
facilities only) and immediately after treatment. 
Off-line PET uses an established PET scanner close to 
the treatment site, often with a CT component. Parodi 
et al compared the in-beam and off-line modalities for 
both synchrotron and cyclotron based proton and ion 
beam therapy facilities [19]. In-room PET uses a 
stand-alone PET scanner positioned within the treat-
ment room for PET acquisition. The advantages and 
limitations of the three modalities are discussed here 
in terms of acquisition time course, data quality and 
cost effectiveness. 
 
 
Fig 3. Relative contributions of major radionuclide species as a function of 
time due to radioactive decay. The simulated production rates in a clinical 
case during the treatment were from Parodi et al[19].  
 
 
Fig 4. Three operational modalities for PET verification of proton therapy. (a), in-beam PET, which uses PET detection panels integrated with the beam 
delivery system; (b), off-line PET, the patients walk to a nearby PET facility for the verification scan; (3), in-room PET, which uses a stand-alone, full-ring PET 
scanner positioned in the treatment room to scan the patient (still in the treatment bed) soon after treatment.   Theranostics 2013, Vol. 3, Issue 10 
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In-beam PET  
Dedicated PET detectors integrated into the 
beam delivery systems were considered by many to 
be the method of choice for the PET verification of 
proton therapy. Currently in-beam PET detectors for 
hardon therapy (including carbon beam and proton 
therapy) are installed or under development in sev-
eral facilities around the world, such as the Gesell-
schaft für Schwerioneneforschung (GSI), Darmstadt, 
Germany [21, 22]; the Heavy Ion Medical Accelerator 
(HIMA) in Chiba, Japan [23]; the CATANA Proton-
therapy Center in Catana, Italy [24], and the National 
Cancer Center (NCC), Kashiwa, Japan [13-15]. The 
most important advantage of in-beam detectors is the 
time course of PET acquisitions. For cyclotron based 
facilities, where the beam is delivered continuously 
during the treatment, PET acquisition can be started 
immediately following the treatment, minimizing the 
delay between treatment and PET acquisition. For 
synchrotron based facilities, where pulsed beam is 
delivered, PET data can even be collected during the 
pauses of beam delivery and continued after the 
treatment as needed. Because of the timely PET data 
acquisition, the PET activity level in the tissue is at the 
highest level for both long half live (11C, 13N, etc) and 
short half live (15O, 10C, etc) components, and the ef-
fect of biological washout of PET activities is mini-
mized. Patient repositioning errors and anatomical 
morphologic changes can also be avoided or mini-
mized as PET data is acquired with the patient still at 
the treatment position. For treatment sessions with 
multiple fields, a short PET scan can be taken after the 
delivery of each field. 
However, integration of a dedicated PET system 
integrated into the beam delivery system is expensive 
and technically demanding [19]. One of the major 
technical challenges is the geometric constrains in a 
treatment environment. In order to ensure an opening 
for the beam portal and flexible patient positioning, 
usually a conventional full-ring detector configura-
tion is not feasible. The time-of-flight technique could 
be used to partially reverse the effects caused by 
non-complete angles of PET data collection [25], but 
also involves  higher cost and implementation com-
plexity. Another challenge is the synchronization of 
the PET data acquisition with the beam control sys-
tem, especially for synchrotron-based facilities col-
lecting PET data between beam spills. PET acquisition 
is not possible during beam extraction because of the 
high prompt gamma and neutron backgrounds. 
The currently employed in-beam PET systems 
mostly use dual-head configurations. At GSI, the de-
tectors are mounted above and below the patient 
couch [22]. At HIMA, the detectors are mounted on a 
rotating gantry port [13]. The limited angle configu-
ration with in-complete angular data collection re-
sulted in lower sensitivity, limited field of views and 
artifacts in reconstructed images. In an effort to allow 
data collection from all angular directions, another 
configuration, OpenPET, is currently under devel-
opment at National Institute of Radiological Science, 
Chiba, Japan [26-30]. The first generation of OpenPET 
(Dual-ring) system design consists two axially sepa-
rated detector rings with the beam passing through 
the gap between the two rings [28]. Although full-ring 
detectors are used in this configuration, only oblique 
lines of response are collected and reconstructed, 
leading to degradations of sensitivity and image 
quality.  The system configuration proposed for the 
second generation of OpenPET (Single-ring) has a 
cylinder shape cut at a slant angle, with the shape of 
each cut end to be an ellipse [30]. The detector ring 
can be rotated to form an accessible open space for the 
beam portal. Even though the data collection is still 
not complete, part of direct lines of responses can be 
collected. The sensitivity was found to be 1.2 times 
higher than the dual-ring Open PET, and the simula-
tion results indicated that uniform resolution can be 
achieved with depth-of-interaction detectors.  
Off-line PET  
Off-line PET uses a commercial scanner outside 
of the treatment room for PET imaging after the 
treatment. Usually this is an established scanner in a 
nearby location that normally also serves other ap-
plications. The pioneer work was done at the Francis 
H. Burr Proton Therapy Center at the Massachusetts 
General Hospital (MGH)[9, 10, 12, 31, 32], Boston, 
followed by other clinical studies at HIMA[33] and 
Proton Therapy Institute at the University of Flori-
da[34]. A new large-scale clinical trial, the MIRANDA 
study, is currently being conducted at University 
Hospital of Heidelberg, Germany [35]. The study 
plans to recruit 240 subjects of different tumor types 
for off-line PET verification of both proton and carbon 
beam therapies.  
The off-line option is attractive because it does 
not require capital investment for the installation of a 
new scanner in the treatment room, and it has no 
impact on the patient throughput in the treatment 
room. The scanner usually has a full-ring configura-
tion, mostly with a CT component. The full-ring con-
figuration allows data collection from all the angular 
directions, and the CT scan allows accurate 
co-registration of PET images with treatment plan-
ning CT and reliable attenuation correction in PET 
reconstructions. However, because the imaging is 
carried out at a remote site, there is a relatively long 
delay for PET acquisitions, depending on the distance  Theranostics 2013, Vol. 3, Issue 10 
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between the treatment and imaging facilities. The 
delay in the MGH studies ranged from ~15 to 30 
minutes, during which time the short-lived radionu-
clide species, most importantly 15O, had decayed. 
Therefore, off-line PET can measure only long half-life 
contributions, mostly from 11C. The performance is 
further degraded by the biological washout of the 
proton induced PET activity, which reduces the ac-
tivity level in the target region (especially for tissues 
with high perfusion rates) and also changes the rela-
tive activity distributions. Other factors affecting the 
performance of off-line PET include the repositioning 
errors and patient anatomical changes during trans-
portation and repositioning. These can be partially 
compensated if an accompany CT scan is taken with 
the PET scan[12]. 
In-room PET  
In-room PET uses a stand-alone PET scanner 
positioned within the treatment room for PET imag-
ing. The first in-room PET studies were also carried 
out at the Francis H. Burr Proton Therapy Center, 
MGH [36]. A compact, mobile brain PET scanner, 
NeuroPET from PhotoDiagnostic Systems, Inc, was 
used for the PET acquisitions. The scanner was posi-
tioned next to the beam nozzle, and the treatment 
couch was rotated and transported to the scan posi-
tion after the treatment. No patient re-positioning was 
necessary. The average delay between treatment and 
PET acquisition was 2.5 minutes 
In-room PET is a compromise between in-beam 
and off-line PET. The cost of a stand-alone PET scan-
ner is significantly lower compared to the installation 
of a PET system integrated into the beam delivery 
system. With no geometric constrains associated with 
the beam delivery and patient positioning, a full-ring 
detector can be used for complete data collection and 
improved image quality. Although there is still a de-
lay between treatment and PET scan, the gap is much 
shorter than in off-line PET, allowing the collection of 
abundant  15O signals. Complications caused by bio-
logical washout, repositioning errors, anatomical 
changes, etc., are also greatly reduced or eliminated. 
In particular, in-room PET is an economical option for 
most hospital-based proton centers that use a cyclo-
tron for proton beam generation, because the beam is 
delivered continuously and no PET data collection is 
possible during the treatment. If a mobile united is 
invested, the PET scanner can also  be shared with 
other applications if desired. However, since the PET 
scan needs to be acquired in the treatment room and 
the time required (including the moving of patient 
bed and the PET acquisition) is likely to be longer 
than with in-beam PET, the in-room PET has a rela-
tively higher impact to the patient throughput in the 
treatment room.  
The largest obstacle encountered in the first ex-
perience of in-room PET was the co-registration be-
tween PET images and the treatment planning CT 
scan. Because the planned dose (and therefore the 
predicted activity distributions to be discussed next) 
was on the CT grid, PET images must be registered 
with the treatment planning CT images for proper 
comparison. However, since only the proton irradi-
ated region was activated, the co-registration was 
difficult without transmission images at the PET scan 
position. In the reported MGH studies the PET and 
CT were registered with concentric CT and PET fidu-
cial markers. The co-registration errors range from 2 
to 5 millimeters, adding uncertainties not only to the 
comparison between PET measurements and predic-
tions, but also to the PET attenuation corrections be-
cause the attenuation map was generated from the 
treatment planning CT co-registered to the PET grid. 
A mobile PET/CT scanner will be available to MGH 
in the near future, which can be expected to signifi-
cantly improve the performance of in-room PET. 
Prediction of PET activity distributions 
Reconstructed PET images must be compared 
with a reference for the treatment verification. Be-
cause proton dose and PET activity distributions are 
not directly related, treatment verification cannot be 
carried out by comparing these two distributions di-
rectly. Up to data two types of reference images have 
been used. In the clinical research conducted at 
HIMA, PET scan taken at an earlier treatment session 
was used as the reference images in fractionated 
therapy to confirm the activated volumes in later ses-
sions [13]. In most other studies, PET measurements 
were compared with predicted PET activity distribu-
tions calculated with Monte Carlo simulations or an-
alytical methods. The proposed approaches for the 
prediction of proton induced activity distributions are 
discussed.  
Monte Carlo simulations 
The predicted activity distributions are most of-
ten  calculated with Monte Carlo simulations using 
open-source particle transportation packages such as 
Fluka[37], Geant4[38], SRIM[39] and MCNPX[40]. The 
simulations are based on the beam parameters and CT 
images from the treatment plans. Proton fluence at 
each voxel surface is first simulated, and then con-
volved with the different cross-section data sets for 
the main reaction channels and scaled with the target 
nuclide densities converted from CT images to obtain 
the distribution of each radionuclide species. Thus 
calculated distributions are then corrected for radio-
active decay and biological washout, taking into con- Theranostics 2013, Vol. 3, Issue 10 
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sideration timing parameters such as the irradiation 
time, delay between treatment and scan, and scan 
duration. The corrected distributions of different ra-
dionuclide species are then summed up and blurred 
with a 3-D Gaussian convolution kernel to model the 
spatial resolution of the PET scanner. Figure 5 shows 
an example of Monte Carlo predicted and measured 
PET distributions in a nasal cavity melanoma clinical 
case. The spatial distribution of measured PET activity 
agreed well with the Monte Carlo prediction in this 
case. 
 
 
Fig 5. A clinical example of Monte Carlo predicted and measured PET 
distributions in a nasal cavity melanoma clinical case. The 20-minute PET 
scan was taken on an in-room, stand-alone PET scanner after a 2-Gy 
fractionated proton dose delivery, with a 1.9 minute delay between the end 
of irradiation and the start of PET scan. (a) Treatment planning dose 
distribution; (2) Monte Carlo simulated dose distribution; (3), Monte Carlo 
simulated PET activity distribution; (d), PET measurement. The spatial 
distribution of measured PET activity agreed well with the Monte Carlo 
prediction in this case [41]. 
 
Uncertainties associated with Monte Carlo sim-
ulations arise from two major sources. The prediction 
relies on the proton fluence and energy distribution in 
each voxel, the nuclear reaction cross sections and the 
tissue density and elemental composition at the voxel 
level. One of the factors limiting the accuracy of PET 
activity prediction is the reliability of the cross section 
data for the relevant reaction channels. A variety of 
experimental values for cross sections of different 
reaction channels have been published, along with 
theoretical values. However, significant discrepancies 
have been found between data sets from different 
sources. Studies by Espana et al [42] indicated that 
range differences of up to 4.4 mm can be found by 
using different cross section data sets in certain cases. 
Another source of uncertainty is CT conversion algo-
rithm, the same factor that also contributes signifi-
cantly to range uncertainty in treatment planning at 
the first place. In the simulations treatment planning 
CT scans are converted to tissue type and density 
maps, from which elemental composition and target 
nuclide density are determined for each voxel. In ad-
dition to CT conversion, the accuracy of PET activity 
prediction is also affected by CT stochastic errors, 
artifacts, resolutions, etc. Espana et al [43] estimated 
that an intrinsic 1 mm uncertainty for PET range veri-
fication is due to CT conversion alone.  
Analytical calculations 
Despite the uncertainties associated with Monte 
Carlo simulations, it is still considered the most ac-
curate approach for the prediction of proton induced 
PET activity distribution. However, considerable time 
and computing power are required for full-blown 
Monte Carlo simulations for each radiation field. 
Therefore, alternative analytical approaches have 
been explored for a simpler and more direct way to 
calculate PET activity distributions. Parodi et al [44] 
first proposed a filtering approach based on Gaussi-
an-power law  convolutions to reconstruct the local 
11C distribution profile near the distal edge. The 
model described the one-dimensional 11C activity 
distribution as a convolution product of the planned 
dose with a small number of reaction-dependent filter 
functions. The filter function is based on a special   
function defined as the convolution of a Gaussian 
with a powerlaw function. Good agreement was 
found between the results of the filtering approach 
and Monte Carlo simulations for simulation data in 
the distal fall-off. Attanasi et al [45] further extended 
the model for 3D activity distribution estimation, and 
included filter functions for other radionuclide species 
(15O et al) as well, so that the model can also be used 
for in-beam and in-room PET verifications. It was 
reported that in general the predicted activity distri-
butions using the filtering approach were in good 
agreement (< 1 mm) with Monte Carlo simulation 
results, but the agreement was limited only to the 
distal region. 
Another analytical method was proposed by 
Miyatake et al using an activity pencil beam (APB) 
algorithm [46]. The pencil beam algorithm is a stand-
ard algorithm of dose calculation in proton therapy. 
In APB, contributions of different positron emitters 
originated from the same target nuclide, such as 11C, 
13N and 15O from 16O via reaction channels 16O (p, 
3p3n) 11C, 16O (p, 2p2n) 13N and 16O (p, pn)15O respec-
tively, are collectively represented as a ‘virtual’ posi-
tron emitter nuclide. The depth activity distribution of 
each virtual nuclide is measured experimentally. An 
~
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activity pencil beam kernel is determined using depth 
and lateral (which is an effect of multiple Coulomb 
scattering) activity distributions measured for each of 
the three major ‘virtual’ nuclei, 12C, 16O and 40Ca. This 
kernel, combined with tissue composition information 
extracted from treatment planning CT images, is used 
for activity distribution calculation using a pencil 
beam algorithm similar to the one used in dose cal-
culations in treatment planning. The algorithm being 
developed is expected to predict PET activity distri-
butions with satisfying accuracy in a few minutes so 
that it can be incorporated into the clinical routine of 
treatment monitoring with an in-beam PET system. 
However, because the measured PET activity distri-
bution contains mixed contributions from radionu-
clide with different half-lives, the PET measurements 
depend greatly on the time course of irradiation and 
data acquisition. These would require virtual nuclei 
activity distributions to be measured for different 
combinations of irradiation and delay times. 
Biological washout  
Regardless of the approach to be used for the 
prediction of the original PET activity production 
distribution, the effect of biological washout must be 
corrected as it can potentially change the activity dis-
tribution significantly. Biological washout of proton 
induced activity starts as soon as the irradiation be-
gins. Although the off-line PET is the most severely 
affected, biological washout also cannot be ignored in 
the in-beam and in-room PET measurements. Unfor-
tunately, up to date there is no dedicated model for 
the correction of biological washout in proton in-
duced PET activity. The currently used washout 
model is based on animal study results using im-
planted radioactive or stable carbon beams [9, 19]. In 
this model, the original PET activity level in each 
voxel, estimated from Monte Carlo simulations or 
analytical calculations, is decomposed into three 
components undergoing fast, medium and slow bio-
logical decays. The tissue type in each voxel is also 
determined based on the Hounsfield Units in the 
treatment planning CT scan. Thresholds of Houns-
field units are set to identify five tissue types: hard 
bone, soft bone, fat, muscle and brain. Tissue-specific 
fractions and biological half-lives are assigned to each 
of the three components in each voxel. The final ac-
tivity distribution is thus calculated based on the nu-
clide radioactive decay rate, assigned biological 
washout parameters and the time course of irradia-
tion and PET acquisition. 
There are many problems with this pre-defined 
biological washout model. First of all, the currently 
used model was adopted from carbon-beam study 
results [47, 48]. Its applicability to proton beam ther-
apy is questionable because projectile fragmentation 
is the dominant contribution in carbon ion therapy, 
while only target fragmentation is possible in proton 
therapy [20]. Secondly, it does not account for varied 
washout rates of different radionuclide species, i.e. 
the same washout parameters are assigned for 11C and 
15O for the same tissue type. Thirdly, the current 
model does not account for local variations, while in 
fact biological clearance rate is greatly affected by 
physiological environment such as local vasculature 
development and perfusion rate. In addition, many 
soft tissue types have very similar CT numbers but 
very different biological washout characters, while in 
the current model they are assigned the same washout 
parameters. On top of all the uncertainties, it is very 
difficult to obtain accurate biological washout pa-
rameters. 
To overcome the limits with the current washout 
model, a kinetic modeling approach was proposed at 
MGH [49] and is currently under development. The 
method is based on the observation that 15O is the 
dominant contribution to PET measurements imme-
diately after proton irradiation. Instead of using 
pre-defined biological clearance parameters, the 
model describes the production and elimination of the 
15O distribution with a differential equation with two 
parameters, the production rate during the irradiation 
and the elimination rate (which is the sum of radioac-
tive and biological clearance rates). The time-activity 
history obtained from dynamically reconstructed PET 
image data is then fitted with the model equation to 
estimate both the production and elimination rates 
simultaneously. A 15O production map can be pro-
duced by fitting the dynamic PET data voxel by voxel, 
and compared to the original 15O distribution pro-
duction prediction directly. The kinetic approach does 
not rely on any arbitrary washout parameters, esti-
mates both the activity production and washout rates 
of 15O, and the variations in biological washout rates 
are automatically taken into consideration. However, 
since  15O dominance is required, the method, if suc-
cessful, would only be applicable to in-beam and 
in-room PET modalities.  
Use of PET images for proton therapy 
verification 
The measured PET images must be compared 
with reference images for treatment verification. Sev-
eral approaches have been proposed and used for the 
use of PET images in proton therapy verification. In 
the in-beam PET studies at HIMA [13], a PET activity 
image was taken every day for fractionated therapy in 
48 patients. The activity image of the first day of the 
treatment was used as a reference, of which the pro-
ton-irradiated volume was calculated. The volume  Theranostics 2013, Vol. 3, Issue 10 
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was also analyzed for treatments of following days 
and compared with the reference. If a difference was 
detected, the causes would be investigated. If the 
changes were conformed to be due to tumor shrink-
age or changes in body shapes, a new CT scan would 
be acquired and a new treatment plan would be used 
to replace the old plan. In this study, re-planning was 
performed for 3 clinical cases out of the 48 subjects.  
While comparing proton irradiated volume at 
different treatment fractions is useful for the moni-
toring of the consistency of the treatments at different 
days, it does not provide information whether the 
actual delivered dose distributions deviate from the 
treatment plans. In order to detect possible errors in 
treatment planning, the measured PET images need to 
be compared with the predicted distributions in a 
proper way. Because the location of the highest en-
ergy deposition in proton therapy is largely deter-
mined by the proton range, current clinical research is 
focused on range verification. Two approaches have 
been used in the off-line studies at MGH. For the 
point-wise approach, range verification was per-
formed by comparing the distal fall-off positions at 
20% to 50% of the last local maximum in the 
depth-activity profiles between PET measurements 
and Monte Carlo predictions [9, 10]. For the shift ap-
proach, the range difference between two depth pro-
files was determined by shifting the normalized 
fall-off regions against each other to minimize the 
sum of absolute differences in the activity values [12, 
31]. The analysis can be performed either on individ-
ual profiles or in the whole fall-off region. In the MGH 
off-line PET study of 23 subjects, the feasibility of 
range verification was found to be restricted to a lim-
ited amount of positions and tumor sites. The ad-
dressed factors contributing to the uncertainties in 
range verification include the reproducibility of 
off-line PET, biological washout effect (especially in 
soft tissue regions), Monte Carlo simulation accuracy, 
motions, beam arrangements, organ movements and 
co-registration accuracy. As a result, proton beam 
range can only be verified within an accuracy of 1~2 
mm when the beam ends in low-perfused bony 
structures of head and neck patients. It was identified 
that intracranial and cervical spine patients, especially 
patients with arteriovenous malformations or metal 
implants, can greatly benefit from the approach [9, 12, 
32]. 
Comparing distal fall-off depth is a simple yet 
very useful figure of merit for range verification. 
However, since the distal fall-off depth determination 
is closely associated with the shape of the activity 
profiles, both the point-wise and shift  approaches 
depend greatly on the accuracy of the activity distri-
bution predictions and measurements. Monte Carlo 
simulations are generally considered the most accu-
rate approach for the prediction of proton induced 
activity distribution, but as discussed previously, 
there are many factors contributing to the uncertain-
ties in simulations, especially for regions with highly 
heterogeneous tissue types having large variations in 
elemental compositions and biological washout rates. 
The accuracy of PET measurements is also a concern, 
especially for off-line PET. Differences of up to 30% 
were observed for repeated measurements on the 
same patient with the same treatment plan scanned 
one week apart, possibly due to statistical errors, 
variations in the elemental composition and changes 
in the biological washout rates at different days [12]. 
In cases of complicated distribution patterns in the 
distal region, the selection of the last local maximum 
is difficult and often subjective, which subsequently 
affects the distal fall-off position determination. A 
more robust method for range verification is very 
desirable. 
In addition to range verification, direct dose 
verification with PET imaging is also actively pur-
sued, which involves reconstructing radiation dose 
distributions from measured PET images. The method 
proposed by Fourkal et al [50] uses an analytical 
model to calculate positron-emitter species matrices 
(PESM) based on proton energy fluence distributions. 
Once the PESM is known, the radiation dose distribu-
tion in a patient is obtained from the deconvolution of 
the 3D PET activity distribution measurements with 
the PESM. The approach proposed by Remmele et al 
[51] is based on the filtering approach proposed by 
Parodi et al [44] and further extended by Attanasi et al 
[45], in which the expected PET images of activity 
distributions are calculated by the convolution of the 
planned dose with specific filter functions. As a re-
verse process, the estimated dose distribution during 
the treatment is calculated using deconvolution 
methods based on the PET images and appropriate 
filter functions. Since this deconvolution is an 
ill-posed inverse problem, regularization techniques 
are used to guarantee a stable solution. Both methods 
demonstrated feasibility with simulation and/or 
phantom data, but applying the dose reconstruction 
techniques on measured patient PET images remains 
a major challenge because of the degradation of image 
qualities by noise, artifacts and limited knowledge on 
biological washout effects. 
Conclusions 
PET imaging has been proved to be a valuable 
technique for the in vivo, in situ verification of proton 
therapy. The three operational modalities, in-beam, 
in-room and off-line, each has its advantages and 
disadvantages. Overall, in-room PET seems to be the  Theranostics 2013, Vol. 3, Issue 10 
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cost-effective option for most hospital-based proton 
centers, except for treatment facilities with an off-line 
scanner available very close by. The performance of 
proton treatment verification with PET is affected not 
only by the PET data detecting systems used, but also 
by the methods used for data processing and inter-
pretation. Additional work is desirable for more reli-
able criteria for range and/or delivered dose verifica-
tion and for the development of an accurate biological 
washout model. Recently a second generation of dose 
delivery techniques, spot beam scanning, is slowly 
becoming commercially available to the proton ther-
apy community. This poses new challenge to the 
treatment verification with PET, and new approaches 
need to be developed accordingly. 
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